About Omixon
Omixon is a company based in Budapest (Hungary) founded in 2009 was acquired by Werfen in November 2024. Omixon offers products and services including NanoTYPE™, Holotype HLA™, HoloGRAFT ONE™, and HLA Twin™. Omixon operates in a competitive market with competitors including MedGenome, Foundation Medicine, Helix, Benchling and Personalis, among others.
- Headquarter Budapest, Hungary
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Omixon Biocomputing Ltd.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Omixon
Omixon offers a comprehensive portfolio of products and services, including NanoTYPE™, Holotype HLA™, HoloGRAFT ONE™, and HLA Twin™.
Nanopore-based long-read sequencing for HLA genotyping applications.
NGS assay and software for HLA typing on Illumina sequencers.
Test for measuring donor-derived cell-free DNA in transplants.
Genotyping software for processing and analyzing HLA data.
People of Omixon
Unlock access to complete
Funding Insights of Omixon
Detailed funding history for Omixon
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in Omixon
Omixon has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Werfen.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Global leader for In Vitro Diagnostic
|
Locked | Locked | Locked |
Investor details for Omixon
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Omixon
Investment portfolio details for Omixon
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Omixon
Detailed financials for Omixon
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Omixon Comparisons
Peer comparison for Omixon
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Omixon
Omixon operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as MedGenome, Foundation Medicine, Helix, Benchling and Personalis, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
DNA sequencing, bioinformatics, and multiomics services are provided.
|
|
| Locked | Locked | Locked |
Genomics-based diagnostic tests for cancer are provided.
|
|
| Locked | Locked | Locked |
Genomic database for clinical research is provided.
|
|
| Locked | Locked | Locked |
Cloud-based bioinformatics platform is offered for biotech research.
|
|
| Locked | Locked | Locked |
Genomic sequencing and diagnosis software is provided for healthcare.
|
|
| Locked | Locked | Locked |
Genetic testing products for health risks and traits are offered.
|
Detailed competitors of Omixon
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Omixon
Complete news archive for Omixon
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Omixon
Omixon was founded in 2009.
Omixon is headquartered in Budapest, Hungary.
Omixon was founded in 2009 in Budapest, Hungary, where operations center on commercializing innovations for targeted Next Generation Sequencing applications in the genomics sector. The Holotype HLA product is offered, integrating a targeted HLA assay with HLA Twin software for high-resolution HLA genotyping. An active grant-funded research program is maintained, and support is provided to scientists and clinicians for analyzing genomic regions such as HLA, KIR, and ABO.
Omixon's top competitors include Foundation Medicine, Helix and MedGenome.
Omixon offers NanoTYPE™, Holotype HLA™, HoloGRAFT ONE™, and HLA Twin™.
Omixon has 1 investor. Key investors include Werfen.